Ok, so I'll have to go back and review the slides
Post# of 148190
(Total Views: 672)
Posted On: 06/06/2020 11:35:59 AM
Re: Coocooburra #36884
Ok, so I'll have to go back and review the slides but one of the hospitals 1/15 died (6.67%). Don't know how to calculate p values but I would have to assume that compared to 31% that is very strong. Can you imagine if Leronlimab can reduce fatality by 78%? Wow.
It also stands to reason that the M2M group would have very few, if not no deaths. Which I believe is why Nader said (paraphrasing) "It doesn't matter if we have 60 or 75 patients. Remember it's a 2:1 ratio and if there is a bad result in the placebo it counts as 2"
This tells me that the Placebo group has had some significantly negative progressions which has created a very strong p value.
I'm trying to year down my logic above (one of my evaluation strategies), but I don't see it. Please, someone tear it down.
It also stands to reason that the M2M group would have very few, if not no deaths. Which I believe is why Nader said (paraphrasing) "It doesn't matter if we have 60 or 75 patients. Remember it's a 2:1 ratio and if there is a bad result in the placebo it counts as 2"
This tells me that the Placebo group has had some significantly negative progressions which has created a very strong p value.
I'm trying to year down my logic above (one of my evaluation strategies), but I don't see it. Please, someone tear it down.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼